An Open-Label Proof-of-Principle Study Testing the Use of an Additional MDMA-Assisted Therapy Session in People who Relapsed after Participating in a Phase 2 Clinical Trial of MDMA-Assisted Therapy to Treat Chronic, Treatment-Resistant Posttraumatic Stress Disorder (PTSD)
This study enrolled three subjects whose PTSD symptoms returned after participating in our flagship Phase 2 clinical trial of MDMA-assisted therapy for PTSD (MP1). This relapse study was designed to determine whether a single additional open-label MDMA-assisted therapy session along with several non-drug therapy sessions was effective at sustaining PTSD symptom reduction.
- Current Status: Completed
- ClinicalTrials.gov Record
- Study Protocol
- Study Timeline
